22358a97-998c-4dd2-a48c-67626c744751
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- PROTEIN_SECRETION+0.400
- UV_RESPONSE_DN+0.400
- ALLOGRAFT_REJECTION+0.300
- ANGIOGENESIS+0.300
- IL6_JAK_STAT3_SIGNALING+0.300
- INFLAMMATORY_RESPONSE+0.300
- INTERFERON_GAMMA_RESPONSE+0.300
- KRAS_SIGNALING_UP+0.300
- TGF_BETA_SIGNALING+0.300
Top 10 suppressed
- MYC_TARGETS_V2-0.600
- E2F_TARGETS-0.500
- OXIDATIVE_PHOSPHORYLATION-0.500
- G2M_CHECKPOINT-0.300
- MYC_TARGETS_V1-0.300
- DNA_REPAIR-0.200
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.200
- UV_RESPONSE_UP-0.200
- ADIPOGENESIS-0.100
- FATTY_ACID_METABOLISM-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CR-7394-01A-11R-2016-07 | — | — | 0.874 |
| 2 | TCGA-AO-A03U-01B-21R-A10J-07 | — | D | 0.867 |
| 3 | efe57fc7-7cf4-432b-86ff-9fd2d1a37b5e | — | — | 0.861 |
| 4 | TCGA-AR-A24V-01A-21R-A169-07 | — | A | 0.859 |
| 5 | TCGA-BH-A1EO-01A-11R-A137-07 | — | A | 0.855 |
| 6 | 20100235.Her2HRneg | — | C | 0.852 |
| 7 | TCGA-A8-A096-01A-11R-A00Z-07 | — | B | 0.848 |
| 8 | TCGA-CR-7392-01A-11R-2016-07 | — | — | 0.848 |
| 9 | TCGA-J2-8192-01A-11R-2241-07 | — | cohortA1 | 0.844 |
| 10 | MDT-AP-3277 | Med | Medulloblastoma | 0.843 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.400 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.200 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |